GeneSys Biologics Pvt Ltd, a leading biotechnology company, has announced its plans to invest between $50-60 Million to establish a state-of-the-art recombinant bulk manufacturing facility in Hyderabad.
The new facility aims to enhance the company’s production capacity and support its growing portfolio of innovative biologic therapies. The decision to set up the large-scale manufacturing facility in Hyderabad, known as the “Pharma Capital of India,” underscores GeneSys Biologics‘ commitment to expanding its presence in the biotech industry and meeting the rising demand for biologics globally. The facility will be designed to adhere to international quality standards and will significantly contribute to India’s position as a major player in the biopharmaceutical sector.
Ravi Patel, CEO of GeneSys Biologics, expressed his enthusiasm for the upcoming project. “We are thrilled to announce our investment in this new recombinant bulk manufacturing facility in Hyderabad. This expansion represents a major milestone for our company and a significant step towards meeting the growing demand for high-quality biologic therapies. The state-of-the-art facility will enable us to scale up our production capabilities and deliver life-saving treatments to patients worldwide.”
He outlined that the new facility will employ cutting-edge technology and advanced manufacturing processes to produce a wide range of recombinant biologic products, including monoclonal antibodies, therapeutic proteins, and vaccines. With the increased capacity, GeneSys Biologics aims to address critical healthcare needs and cater to the rising demand for affordable and effective biologic treatments.
K T Rama Rao, Telangana IT and Industries Minister, said the new plant will contribute to the growth of Hyderabad’s biotech sector and facilitate the company’s ongoing collaboration with U.S.-based Civica Rx, a non-profit generic drug company, to manufacture and distribute affordable insulin.
GeneSys is focused on developing and manufacturing high-quality, affordable medications, including multiple insulin analogue biosimilars.